Studies Show Shorter, Less Toxic Drug Combinations Could Be Effective In Treating Drug-Resistant TB
Devex: 3 innovations that could transform TB diagnosis and care
“Ending global tuberculosis will require new diagnostic tools, new ways to support adherence to treatment, new drug regimens, and a vaccine, experts told Devex at the 48th Union World Conference on Lung Health. … Experts including those gathered in Guadalajara this week are working tirelessly to develop new tools that can transform the TB landscape, including technologies that target diagnosis, treatment, and delivery. Devex spoke with three TB researchers who presented new findings that they hope will transform efforts to combat the epidemic…” (Cousins, 10/16).
New York Times: In Early Results, Shorter Treatment for Tuberculosis Proves Effective
“Taking the right antibiotics for just nine months may be as effective against drug-resistant tuberculosis as taking them for two years, as is currently recommended, according to preliminary findings from an international study. Results from the trial, which is overseen by the International Union Against Tuberculosis and Lung Disease and UCL (formerly the University College London), were released at a conference in Mexico…” (McNeil, 10/13).
Wall Street Journal: New Treatments for Drug-Resistant TB Get a Boost
“New research released this week bolsters the case for more effective, less toxic, and shorter treatment regimens for drug-resistant tuberculosis, offering hope for patients suffering from a disease that is notoriously difficult to treat. The three separate studies are among several that TB researchers have under way to develop new drug combinations to replace current treatments that last as long as two years, involve up to 15,000 pills, and can cause deafness, renal failure, and other debilitating effects. Many patients are never cured…” (McKay, 10/13).